Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
China
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality Peking University People's Hospital, Beijing, Beijing Municipality Affiliated Hospital of Chengde Medical University, Chengde, Hebei The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Shiyan People's Hospital, Shiyan, Hubei